申请人:Hoechst Aktiengesellschaft
公开号:US05773447A1
公开(公告)日:1998-06-30
The present invention relates to tertiary 4-amino-2-ureidopyrimidine-5-carboxamides of formula I: ##STR1## in which R.sup.1 is (C.sub.1 -C.sub.8)-alkyl wherein one or more H are replaced by F; R.sup.2 is selected from the group consisting of F, Cl, Br, H, --O--(C.sub.1 -C.sub.8)-alkyl and (C.sub.1 -C.sub.8)-alkyl, wherein one or more of the H of the alkyls can be replaced by F; R.sup.3 is selected from the group consisting of F, Cl, Br, H, --O--(C.sub.1 -C.sub.4)-alkyl and (C.sub.1 -C.sub.4)-alkyl, wherein one or more of the H of the alkyl can be replaced by F; R.sup.4 is CF.sub.3 or OCF.sub.3 ; and their physiologically tolerable salts. Process for preparing the compounds of formula I are also described. The compounds are suitable for the treatment of disorders of lipid metabolism.
本发明涉及公式I的三级4-氨基-2-脲基嘧啶-5-羧酰胺:##STR1##
其中R.sup.1为(C.sub.1-C.sub.8)烷基,其中一个或多个H被F取代; R.sup.2选择自F,Cl,Br,H,--O--(C.sub.1-C.sub.8)烷基和(C.sub.1-C.sub.8)烷基的群,其中烷基的一个或多个H可以被F取代; R.sup.3选择自F,Cl,Br,H,--O--(C.sub.1-C.sub.4)烷基和(C.sub.1-C.sub.4)烷基的群,其中烷基的一个或多个H可以被F取代; R.sup.4为CF.sub.3或OCF.sub.3;以及其生理耐受性盐。还描述了制备公式I化合物的过程。这些化合物适用于治疗脂质代谢障碍。